REG - PureTech Health PLC - PDMR Notification

Puretech HealthAnnouncement

04/07/2025 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250704:nRSD7008Pa&default-theme=true

RNS Number : 7008P  PureTech Health PLC  04 July 2025

04 July 2025

PureTech Health plc

 

PDMR Notifications

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to giving life to new classes
of medicine to change the lives of patients with devastating diseases,
announces that award of restricted share units ("RSUs") granted by PureTech on
04 March 2024 to Robert Lyne, Chief Portfolio Officer ("PDMR") pursuant to its
Performance Share Plan ("PSP") 25% of the shares vested on 01 February 2025.

The PDMR received vested ordinary shares (after deduction of shares for taxes)
on 01 July 2025. The market price per ordinary share in the Company used to
calculate the amount payable to the PDMR and the amount of shares to be issued
to PDMR was 125.93 pence, being the average closing price of the Company's
shares over the three-trading day period prior to issuance, and the exchange
rate used to calculate the cash payment and amount of share settlement was
£1: $1.37.

The Company has been notified that the PDMR has sold a total of 33,561
ordinary shares in the Company ("Shares") on 01 July 2025 at a price of 125.05
pence per share and bought on 01 July 2025, into his SIPP, a total of 33,561
Shares at the price of 125.78 pence per share.

The Company's total issued ordinary share capital is 257,927,489 shares after
the share issuance to the PDMR, 17,639,479 shares of which are held in
treasury by the Company.

PDMR Notification

 

The information contained in the below notification is disclosed in accordance
with Article 19 of the EU Market Abuse Regulation.

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Robert Lyne

 2   Reason for the notification
 a)  Position/status                                              Chief Portfolio Officer
 b)  Initial notification/Amendment                               Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         PureTech Health plc
 b)  LEI                                                          213800LVPDNO2Z9T9I39
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of PureTech Health plc

                                                                  ISIN GB00BY2Z0H74
 b)  Nature of the transaction                                    Issuance of ordinary shares in settlement of certain vested RSUs under the
                                                                  PureTech Health Performance Share Plan and Share Disposal
 c)  Price(s) and volume(s)                                       Recipient    Price     Amount
                                                                  Robert Lyne  0.01 GBP  33,561 ordinary shares
 d)  Aggregated information                                       Price     Aggregate Volume

- Aggregated volume                                         0.01 GBP  33,561 ordinary shares

- Price
 e)  Date of the transaction                                      01 July 2025
 f)  Place of the transaction                                     London Stock Exchange (XLON)

b)

Nature of the transaction

Issuance of ordinary shares in settlement of certain vested RSUs under the
PureTech Health Performance Share Plan and Share Disposal

c)

Price(s) and volume(s)

 Recipient    Price     Amount
 Robert Lyne  0.01 GBP  33,561 ordinary shares

d)

Aggregated information

 -  Aggregated volume

 -  Price

 Price     Aggregate Volume
 0.01 GBP  33,561 ordinary shares

e)

Date of the transaction

01 July 2025

f)

Place of the transaction

London Stock Exchange (XLON)

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep portfolio through its
experienced research and development team and its extensive network of
scientists, clinicians, and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration-enabling studies. All of the underlying
programs and platforms that resulted in this portfolio of therapeutic
candidates were initially identified or discovered and then advanced by
the PureTech team through key validation points.

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBIGDRDXGDGUX